Equities research analysts at Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Wednesday, The Fly reports. The firm set a “buy” rating on the biotechnology company’s stock.
Several other brokerages also recently weighed in on SRPT. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer reissued a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. UBS Group reissued an “outperform” rating and issued a $56.51 target price (down previously from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th. Finally, Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $63.79.
Sarepta Therapeutics (NASDAQ:SRPT) traded up $0.30 during trading on Wednesday, hitting $58.55. 1,660,000 shares of the company traded hands, compared to its average volume of 1,440,000. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $59.00. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The stock has a market cap of $3,780.00, a price-to-earnings ratio of -28.70 and a beta of 1.37.
In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the sale, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares in the last quarter. HealthCor Management L.P. increased its position in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares in the last quarter. Jennison Associates LLC increased its position in Sarepta Therapeutics by 103.9% during the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after purchasing an additional 582,894 shares in the last quarter. Eagle Asset Management Inc. increased its position in Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after purchasing an additional 207,810 shares in the last quarter. Finally, Emerald Advisers Inc. PA increased its position in Sarepta Therapeutics by 2.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after purchasing an additional 18,077 shares in the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
